PROBIOTIX HEALTH LS-05 (X90) — Working Capital to Net Assets Ratio
PROBIOTIX HEALTH LS-05 (X90) has a Working Capital to Net Assets ratio of 90.8% as of June 2025. Working capital of €1.62 Million (current assets of €2.16 Million minus current liabilities of €538.00K) is measured against net assets of €1.79 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See PROBIOTIX HEALTH LS-05 net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
PROBIOTIX HEALTH LS-05 Working Capital to Net Assets (2022–2024)
This chart shows how PROBIOTIX HEALTH LS-05's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2022 to 2024. As of June 2025, the ratio stands at 90.8%, reflecting working capital of €1.62 Million against net assets of €1.79 Million EUR. Check tangible equity quality of PROBIOTIX HEALTH LS-05 to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for PROBIOTIX HEALTH LS-05 (2022–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for PROBIOTIX HEALTH LS-05 from 2022 to 2024, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see X90 market cap.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 90.5% | €1.74 Million | €1.92 Million | €1.93 Million | €194.00K | ▲ +5.2 pp |
| 2023 | 85.2% | €1.30 Million | €1.53 Million | €1.87 Million | €566.00K | ▼ -2.8 pp |
| 2022 | 88.0% | €1.75 Million | €1.99 Million | €2.02 Million | €272.04K | — |